Welcome to the Oligonucleotides & Peptides Formulation & Process Development Summit
The Oligos & Peptides Formulation & Process Development Summit 2022 is the only forum honing in on formulation and process development with an end-to-end perspective. In August, we will specifically be honing into the CMC and regulatory compliance to support scale-up, GMP compliance and tech transfer.
Working with complex macromolecules, specifically double stranded DNA/RNAs, macrocyclic peptides, peptide-oligonucleotide conjugates, requires collaboration to redefine formulation, process development and CMC requirements now, in order to deliver these novel treatments to patients with quality and affordability in mind.
Attend this summit to hear from pioneers including AstraZeneca, Amgen, Janssen, Eli Lilly & Company who’ll be sharing their experience and advances. Here’s a sneak preview:
Looking into CMC and regulatory compliance – assessing regulatory advances to control impurities with Nadim Akhatar, Senior Principal Scientist, New Modalities, AstraZeneca and Marc Lemaitre, Principal, ML Consult
Explore the role of characterization techniques in formulation and analytical development of small oligonucleotides in an interactive roundtable discussion with Ranajoy Majumdar, Director – Analytical Development, Eli Lilly
Oliver Thiel, Executive Director Process Development, Drug Substance Technologies, Amgen will walk you through sustainable manufacturing and novel green chemistry
Learn about emerging formulation strategies to improve oligonucleotide PK and delivery to extra-hepatic tissues with Robert Shaffer, COO & Founder, Vrata Therapeutics
Delve into scale up and emerging technologies – Michael Hellerstein, VP Product Development, Vaxxinity will take you through how to successfully partner in tech transfer to CROs and CDMOs
Walk away from this 3 day summit with clarity, actionable insights, lessons learned and your questions answered on oligos and peptides formulation and process development.